RTOG-0825
|
RTOG
|
Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide plus Bevacizumab versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
RTOG-0848
|
RTOG
|
A Phase II-R and A Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma <br>
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
RTOG-0920
|
RTOG
|
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
RTOG-0924
|
RTOG
|
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
RTOG-1005
|
RTOG
|
A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
RTOG-1010
|
RTOG
|
A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
RTOG-1016
|
RTOG
|
Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
RTOG-1112
|
RTOG
|
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
RTOG-1115
|
RTOG
|
Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700 For Men with High Risk Prostate Cancer
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
RTOG-1216
|
RTOG
|
Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk, Squamous Cell Cancer of the Head and Neck
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|